XML 106 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
3 Months Ended 12 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2021 and March 31, 2021, by level, within the fair value hierarchy (in thousands):
 
    
As of June 30, 2021
    
As of March 31, 2021
 
    
Level 1
    
Level 2
    
Level 3
    
Balance as
of June 30,
2021
    
Level 1
    
Level 2
    
Level 3
    
Balance as
of March 31,
2021
 
Assets:
                                                                       
Money market funds
   $ 1,340,662      $ —        $ —        $ 1,340,662      $ 1,420,597      $ —        $ —        $ 1,420,597  
Investment in Sio common shares
     50,716        —          —          50,716        48,487        —          —          48,487  
Investment in Arbutus common shares
     48,521        —          —          48,521        53,325        —          —          53,325  
Investment in Arbutus convertible preferred shares
     —          69,187        —          69,187        —          76,037        —          76,037  
Other investment
     11,935        —          —          11,935        11,129        —          —          11,129  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total assets at fair value
   $ 1,451,834      $ 69,187      $ —        $ 1,521,021      $ 1,533,538      $ 76,037      $ —        $ 1,609,575  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                                                       
Debt issued by Dermavant to NovaQuest
  
$
—       
$
—       
$
155,200     
$
155,200     
$
—       
$
—       
$
150,100     
$
150,100  
Liability instruments measured at fair value
     —          —          5,906        5,906        —          —          67,893        67,893  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities at fair value
   $ —        $ —        $ 161,106      $ 161,106      $ —        $ —        $ 217,993      $ 217,993  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and 2020, by level, within the fair value hierarchy (in thousands):
 
   
As of March 31, 2021
   
As of March 31, 2020
 
   
Level 1
   
Level 2
   
Level 3
   
Balance as of
March 31,
2021
   
Level 1
   
Level 2
   
Level 3
   
Balance as of
March 31,
2020
 
Assets:
                                                               
Money market funds
  $ 1,420,597     $ —       $ —       $ 1,420,597     $ 1,874,662     $ —       $ —       $ 1,874,662  
Investment in Sio common shares
    48,487       —         —         48,487       45,329       —         —         45,329  
Investment in Arbutus common shares
    53,325       —         —         53,325       16,174       —         —         16,174  
Investment in Arbutus convertible preferred shares
    —         76,037       —         76,037       —         23,062       —         23,062  
Other investments
    11,129       —         —         11,129       8,880       —         —         8,880  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total assets at fair value
  $ 1,533,538     $ 76,037     $ —       $ 1,609,575     $ 1,945,045     $ 23,062     $ —       $ 1,968,107  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Liabilities:
                                                               
Debt held by Dermavant with NovaQuest
  $ —       $ —       $ 150,100     $ 150,100     $ —       $ —       $ 89,100     $ 89,100  
Liability instruments measured at fair value
    —         —         67,893       67,893       —         —         102,373       102,373  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total liabilities at fair value
  $ —       $ —       $ 217,993     $ 217,993     $ —       $ —       $ 191,473     $ 191,473  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement  
The fair value of the options to acquire the Company’s interest in Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant (collectively, the “Option Vants”) granted to Sumitomo under the Sumitomo Transaction Agreement as of March 31, 2021 and 2020 was calculated using significant unobservable inputs including the following:
 
    
Range or Point Estimate Used
Input
  
As of March 31, 2021
 
As of March 31, 2020
Time to expiration (in years)
   3.59   0.49 - 4.59
Risk-free rate
   0.52%   0.15% - 0.35%
Volatility
  
89.0% - 95.0%
 
91.0% - 110.0%
Schedule of change in the fair value of the derivative warrant liabilities
The changes in fair value of the Level 3 liabilities during the three months ended June 30, 2021 and 2020 were as follows (in thousands):
 
Balance at March 31, 2020
   $ 191,473  
Changes in fair value of debt and liability instruments, included in net loss
     17,125  
Liability instruments disposed due to deconsolidation of subsidiary
     (3,325
    
 
 
 
Balance at June 30, 2020
   $ 205,273  
    
 
 
 
 
 
 
 
 
Balance at March 31, 2021
   $ 217,993  
Changes in fair value of debt and liability instruments, included in net loss
     4,585  
Termination of DSP Options
     (61,472
    
 
 
 
Balance at June 30, 2021
   $ 161,106  
    
 
 
 
The changes in fair value of the Level 3 liabilities during the years ended March 31, 2021 and 2020 were as follows (in thousands):
 
Balance at March 31, 2019
   $ 103,628  
Issuance of liability instruments measured at fair value
     101,567  
Changes in fair value of debt and liability instruments, included in net loss
     (13,722
    
 
 
 
Balance at March 31, 2020
     191,473  
Changes in fair value of debt and liability instruments, included in net loss
     29,845  
Liability instruments disposed due to deconsolidation of subsidiary
     (3,325
    
 
 
 
Balance at March 31, 2021
   $ 217,993